DEF: Progyny, Inc. Announces Details for 2025 Annual Stockholders Meeting
Definitive Proxy Statement
Progyny, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on May 22, 2025, to vote on director elections, ratification of the independent auditor, and executive compensation.
Summary
- Progyny, Inc. is holding its Annual Meeting of Stockholders virtually on May 22, 2025.
- Stockholders will vote on the election of three Class III directors, the ratification of Ernst & Young LLP as the independent auditor, and the approval of executive compensation.
- The record date for the meeting is March 28, 2025.
- The proxy materials, including the notice of the meeting and the annual report, are available online at www.edocumentview.com/PGNY.
- Stockholders can vote online during the meeting or in advance by internet, telephone, or mail.
Sentiment
Score: 8
Explanation: The document presents a positive outlook with strong financial performance and growth, indicating a favorable sentiment.
Positives
- Progyny achieved record revenue of $1.167 billion in 2024, a 7.2% increase year-over-year.
- The company added over 80 new clients and 1.1 million new covered lives.
- Progyny's Net Promoter Score (NPS) is high, indicating strong customer satisfaction.
- Clinical outcomes remain superior to national averages.
- Stockholders overwhelmingly approved the company's executive compensation in the previous say-on-pay vote.
Future Outlook
The company expects to serve an estimated 6.7 million covered lives in 2025 and continue expanding its solutions in pregnancy, postpartum, and menopause.
Industry Context
Progyny operates in the healthcare industry, specifically within fertility, family building, and women's health benefits. The company competes with other benefits providers and healthcare organizations offering similar services.
Comparison to Industry Standards
- Progyny's clinical outcomes with respect to single embryo transfer rates, pregnancy rate, miscarriage rate, live birth rate, and IVF multiples rate remained superior to national averages.
- The company's Net Promoter Score (NPS) of +79 for fertility benefits and +84 for Progyny Rx are industry-leading.
Stakeholder Impact
- Stockholders have the opportunity to vote on key company matters.
- Employees are guided by the company's mission and corporate responsibility initiatives.
- Members benefit from transformative fertility, family building, and women's health benefits.
- Employer clients can offer comprehensive and equitable benefits to their employees.
Next Steps
- Stockholders are encouraged to vote their shares in advance of the Annual Meeting.
- The company will file a Current Report on Form 8-K to disclose the final voting results after the Annual Meeting.
Key Dates
| Date | Description |
|---|---|
| 2017-12-31 | Financial data included in the report covers periods up to this date. |
| 2018-12-31 | Financial data included in the report covers periods up to this date. |
| 2019-12-31 | Financial data included in the report covers periods up to this date. |
| 2020-12-31 | Financial data included in the report covers periods up to this date. |
| 2021-12-31 | Financial data included in the report covers periods up to this date. |
| 2022-12-31 | Financial data included in the report covers periods up to this date. |
| 2023-12-31 | Financial data included in the report covers periods up to this date. |
| 2024-01-01 | Start date for financial year covered in the report. |
| 2024-12-31 | End date for financial year covered in the report; Annual Report on Form 10-K for the fiscal year ended December 31, 2024 is available. |
| 2025-03-28 | Record date for the Annual Meeting. |
| 2025-04-11 | Expected date of mailing the Notice of Internet Availability of Proxy Materials. |
| 2025-05-22 | Date of the Annual Meeting of Stockholders. |
| 2025-12-12 | Deadline for stockholder proposals to be included in next year's proxy materials. |
| 2026-01-22 | Earliest date for submitting a proposal or director nomination at the 2026 annual meeting that is not to be included in next year's proxy materials. |
| 2026-02-21 | Latest date for submitting a proposal or director nomination at the 2026 annual meeting that is not to be included in next year's proxy materials. |
Keywords
Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Ernst & Young, Voting, Progyny, Governance, Shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.